Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikolaj Bak

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Psychological Medicine|May 9, 2018
Cortical structures and their clinical correlates in antipsychotic-naïve schizophrenia patients before and after 6 weeks of dopamine D2/3 receptor antagonist treatmentKasper Jessen, Egill Rostrup, Rene C W Mandl, et al.
Frontiers in Psychiatry|February 13, 2019
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral DensityRobert Eriksson, Brian V Broberg, Pelle L Ishøy, et al.
Schizophrenia Research. Cognition|July 26, 2017
Social cognition in patients at ultra-high risk for psychosis: What is the relation to social skills and functioning?Louise B Glenthøj, Birgitte Fagerlund, Carsten Hjorthøj, et al.
Psychoneuroendocrinology|June 22, 2015
Postprandial prolactin suppression appears absent in antipsychotic-treated male patientsKlara Coello, Brian V Broberg, Nikolaj Bak, et al.
Diabetes, Obesity & Metabolism|October 8, 2016
Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trialPelle L Ishøy, Filip K Knop, Brian V Broberg, et al.
Psychological Medicine|December 19, 2018
Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patientsBjørn H Ebdrup, Martin C Axelsen, Nikolaj Bak, et al.
Diabetes, Obesity & Metabolism|January 10, 2018
Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trialBjørn H Ebdrup, Brian V Broberg, Pelle L Ishøy, et al.
Schizophrenia Research|November 6, 2017
Examining speed of processing of facial emotion recognition in individuals at ultra-high risk for psychosis: Associations with symptoms and cognitionLouise Birkedal Glenthøj, Birgitte Fagerlund, Nikolaj Bak, et al.
Schizophrenia Bulletin|February 21, 2015
Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment OutcomeSanne Wulff, Lars Hageman Pinborg, Claus Svarer, et al.
Diabetes, Obesity & Metabolism|September 7, 2018
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysisDan Siskind, Margaret Hahn, Christoph U Correll, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Psychological Medicine|May 9, 2018
Cortical structures and their clinical correlates in antipsychotic-naïve schizophrenia patients before and after 6 weeks of dopamine D2/3 receptor antagonist treatmentKasper Jessen, Egill Rostrup, Rene C W Mandl, et al.
Frontiers in Psychiatry|February 13, 2019
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral DensityRobert Eriksson, Brian V Broberg, Pelle L Ishøy, et al.
Schizophrenia Research. Cognition|July 26, 2017
Social cognition in patients at ultra-high risk for psychosis: What is the relation to social skills and functioning?Louise B Glenthøj, Birgitte Fagerlund, Carsten Hjorthøj, et al.
Psychoneuroendocrinology|June 22, 2015
Postprandial prolactin suppression appears absent in antipsychotic-treated male patientsKlara Coello, Brian V Broberg, Nikolaj Bak, et al.
Diabetes, Obesity & Metabolism|October 8, 2016
Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trialPelle L Ishøy, Filip K Knop, Brian V Broberg, et al.
Psychological Medicine|December 19, 2018
Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patientsBjørn H Ebdrup, Martin C Axelsen, Nikolaj Bak, et al.
Diabetes, Obesity & Metabolism|January 10, 2018
Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trialBjørn H Ebdrup, Brian V Broberg, Pelle L Ishøy, et al.
Schizophrenia Research|November 6, 2017
Examining speed of processing of facial emotion recognition in individuals at ultra-high risk for psychosis: Associations with symptoms and cognitionLouise Birkedal Glenthøj, Birgitte Fagerlund, Nikolaj Bak, et al.
Schizophrenia Bulletin|February 21, 2015
Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment OutcomeSanne Wulff, Lars Hageman Pinborg, Claus Svarer, et al.
Diabetes, Obesity & Metabolism|September 7, 2018
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysisDan Siskind, Margaret Hahn, Christoph U Correll, et al.
Pageof 3